You are in: eMedicine Specialties > Emergency Medicine > OPHTHALMOLOGY Hordeolum and StyeArticle Last Updated: Mar 11, 2008AUTHOR AND EDITOR INFORMATIONAuthor: Michael Bessette, MD, Director of Emergency Medicine, Bayonne Medical Center Michael Bessette is a member of the following medical societies: American College of Emergency Physicians Editors: Robin R Hemphill, MD, MPH, Associate Professor, Director, Disaster Preparedness, Department of Emergency Medicine, Vanderbilt University Medical Center; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Douglas Lavenburg, MD, Clinical Professor, Department of Emergency Medicine, Christiana Care Health Systems; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital Author and Editor Disclosure Synonyms and related keywords: chalazion, chalazia, infection of the eyelid margin, inflammation of the eyelid margin, external hordeolum, internal hordeolum, Staphylococcus aureus, Zeiss sebaceous glands, Moll sebaceous glands, meibomian glands, blepharitis, diabetes, seborrhea INTRODUCTIONBackgroundA hordeolum (ie, stye) is a localized infection or inflammation of the eyelid margin involving hair follicles of the eyelashes (ie, external hordeolum) or meibomian glands (ie, internal hordeolum). A chalazion is a painless granuloma of the meibomian glands. A hordeolum usually is painful, erythematous, and localized. It may produce edema of the entire lid. Purulent material exudes from the eyelash line in external hordeola, while internal hordeola suppurate on the conjunctival surface of eyelid. PathophysiologyStaphylococcus aureus is the infectious agent in 90-95% of cases of hordeolum. An external hordeolum arises from a blockage and infection of Zeiss or Moll sebaceous glands. An internal hordeolum is a secondary infection of meibomian glands in the tarsal plate. Both types can arise as a secondary complication of blepharitis. Untreated, the disease may spontaneously resolve or it may progress to chronic granulation with formation of a painless mass known as a chalazion. Chalazia can be quite large and can cause visual disturbance by deforming the cornea. Generalized cellulitis of the eyelid may occur if an internal hordeolum is untreated. Most morbidity is secondary to improper drainage. Proper technique and drainage precautions are described in Treatment. FrequencyUnited StatesExact incidence of the disease is unknown, but it is a common entity. InternationalNo difference exists between US and international occurrence. SexNo sexual predilection exists. AgeA slight increase in incidence is observed in the third to fifth decades of life. CLINICALHistory
PhysicalCompletely examine the area around the orbit, the eye, and the conjunctival surface. Carefully inspect the underside of the eyelid to avoid missing an internal hordeolum.
Causes
DIFFERENTIALSChalazion Conjunctivitis Corneal Abrasion
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Bacitracin ophthalmic ointment (AK-Tracin) |
|---|---|
| Description | Prevents transfer of mucopeptides into growing cell wall; inhibits bacterial cell wall synthesis. |
| Adult Dose | Severe infections: 0.25- to 0.50-in ribbon q3-4h for 7-10 d into conjunctival sac(s) Mild-to-moderate infections: Apply bid/tid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; vaccinia; varicella; epithelial herpes simplex keratitis; mycobacterial infections; fungal diseases of the eye; patients using steroid combinations after uncomplicated removal of a corneal foreign body |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Ophthalmic ointments may delay healing of corneal epithelia; in deep seated infections of the eye, supplement with systemic medications; prolonged use may result in overgrowth of nonsusceptible organisms |
| Drug Name | Tobramycin ophthalmic solution or ointment (Tobrex, AKTob) |
|---|---|
| Description | Interferes with bacterial protein synthesis by binding to 30S and 50S ribosomal subunits, which results in a defective bacterial cell membrane; available as solution, ointment, and lotion |
| Adult Dose | Solution: 1-2 gtt q4h during waking hours and less frequently at night; in severe infections, instill 2 gtt q30-60min initially, followed by less frequent intervals Ointment: Apply 0.5-inch ribbon in conjunctival sac bid/tid; in severe infections, apply q3-4h |
| Pediatric Dose | <2 years: Not established >2 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Effects decrease when used concurrently with gentamicin |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Do not use in deep-seated ocular infections or in those that may become systemic; prolonged use of antibiotics may result in bacterial or fungal overgrowth of nonsusceptible organisms |
| Drug Name | Erythromycin (EES, E-Mycin, Ery-Tab) |
|---|---|
| Description | First-choice treatment when systemic therapy is indicated; also indicated for treatment of infections caused by susceptible strains of microorganisms, including S aureus. |
| Adult Dose | 250 mg erythromycin stearate/base (or 400 mg ethylsuccinate) q6h PO 1 h ac, or 500 mg q12h Alternatively, 333 mg PO q8h; increase to 4 g/d depending on severity of infection |
| Pediatric Dose | 30-50 mg/kg/d (15-25 mg/lb/d) PO divided q6-8h; double dose for severe infection |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
| Drug Name | Dicloxacillin (Dycill, Dynapen) |
|---|---|
| Description | For treatment of infections caused by penicillinase-producing staphylococci. May be used to initiate therapy when a staphylococcal infection is suspected. |
| Adult Dose | 125-250 mg PO q6h |
| Pediatric Dose | <40 kg: 12.5 mg/kg/d PO divided q6h >40 kg: 125 mg PO q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Decreases efficacy of oral contraceptives; increases effects of anticoagulants; probenecid and disulfiram may increase penicillin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Monitor PT in patients taking anticoagulant medications; toxicity may increase in patients renally impaired |
| Drug Name | Tetracycline (Sumycin) |
|---|---|
| Description | Treats susceptible bacterial infections of both gram-positive and gram-negative organisms as well as infections caused by mycoplasmal, chlamydial, and rickettsial organisms; inhibits bacterial protein synthesis by binding with 30S and possibly 50S ribosomal subunit(s) of susceptible bacteria |
| Adult Dose | Mild-to-moderate infections: 500 mg PO bid or 250 mg PO qid for 7-14 d Severe infections: 500 mg PO qid for 7-14 d |
| Pediatric Dose | <8 years: Not recommended >8 years: 10-20 mg/lb/d PO (25-50 mg/kg/d) divided qid |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy; tetracyclines can increase hypoprothrombinemic effects of anticoagulants |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Cloxacillin (Cloxapen, Tegopen) |
|---|---|
| Description | For treatment of infections caused by penicillinase-producing staphylococci. May be used to initiate therapy when a staphylococcal infection is suspected. |
| Adult Dose | 250-500 mg PO q6h |
| Pediatric Dose | <20 kg: 50-100 mg/kg/d PO divided q6h >20 kg: 250 mg PO q6h |
| Contraindications | Documented hypersensitivity |
| Interactions | Decreases efficacy of oral contraceptives; may decrease effects of anticoagulants; probenecid and disulfiram may increase penicillin levels |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Monitor PT in patients taking anticoagulant medications; toxicity may increase in patients renally impaired |
| Media file 1: Hordeolum pointing internally | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Internal side of the same hordeolum | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Mar 11, 2008